Drug
Azeliragon clinical trials
Also written TTP488 and PF-04494700.
- studies test it
- 15
- open now
- 3
- in phase 3
- 3
- first study started
- 2005
Keep track of what changes. Save the azeliragon studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
15 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 6
Cantex Pharmaceuticals (3) · Pfizer (3) · vTv Therapeutics (3) · NYU Langone Health (1) · The University of Texas Medical Branch, Galveston (1) · Akshitkumar MIstry (1) · Washington University School of Medicine (1) · Baptist Health South Florida (1)
Studies
Open first, then newest update. How each study uses azeliragon is read from its arms, and is right about nine times in ten.
Testing it · 15
- Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade GliomasNot yet recruitingPhase 2Akshitkumar MIstryNCT07694089Written as Azeliragon
- Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed GlioblastomaRecruitingEarly Phase 1Washington University School of MedicineNCT06831526Written as Azeliragon
- Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic CancerRecruitingPhase 1/2Cantex PharmaceuticalsNCT05766748Written as Azeliragon
- Azeliragon and Chemoradiotherapy in Newly Diagnosed GlioblastomaCompletedPhase 1/2Cantex PharmaceuticalsNCT05635734Written as Azeliragon 5 mg
- Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain MetastasesSuspendedPhase 1/2Baptist Health South FloridaNCT05789589Written as Azeliragon
- Concurrent Azeliragon With Craniospinal IrradiationActive, not recruitingPhase 1NYU Langone HealthNCT06724926Written as Azeliragon
- Azeliragon in MGMT Unmethylated GlioblastomaActive, not recruitingPhase 2Cantex PharmaceuticalsNCT05986851Written as Azeliragon
- A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or PneumoniaActive, not recruitingPhase 2/3The University of Texas Medical Branch, GalvestonNCT05815485Written as Azeliragon
- Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with GlioblastomaWithdrawnPhase 1City of Hope Medical CenterNCT05773664Written as Azeliragon
- Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose ToleranceTerminatedPhase 2vTv TherapeuticsNCT03980730Written as Azeliragon
- 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)TerminatedPhase 3vTv TherapeuticsNCT02916056Written as Azeliragon 5mg
- Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's DiseaseTerminatedPhase 3vTv TherapeuticsNCT02080364Written as Azeliragon
- A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00566397Written as PF-04494700
- 6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent AlbuminuriaCompletedPhase 2PfizerNCT00287183Written as PF-04494700 (TTP488)
- A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's PatientsCompletedPhase 2PfizerNCT00141661Written as PF-04494700 - Low Dose Arm
Given in every arm · 2 — azeliragon is usual care beside what is tested
- Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast CancerNot yet recruitingPhase 1/2The Methodist Hospital Research InstituteNCT07785856Written as Azeliragon
- RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast CancerRecruitingPhase 1/2Georgetown UniversityNCT05256745Written as TTP488
Codes
What other systems call azeliragon · ClinicalTrials.gg INT001229
- MeSH (NLM) C000655744azeliragonConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LPU25F15UQAZELIRAGONConfirmed FDA, NLM, Wikidata
- Wikidata Q27074825azeliragonConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174675AzeliragonOne source FDA
- DrugBank DB12689One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000655744 | azeliragon | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LPU25F15UQ | AZELIRAGON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074825 | azeliragon | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174675 | Azeliragon | One source FDA |
| DrugBank | DB12689 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.